P
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Phuc Tran's research focuses on the discovery and development of novel therapeutic agents, with a particular emphasis on oncology and targeted protein degradation. Tran has investigated small molecules designed to inhibit specific kinases implicated in cancer, such as FLT3-ITD and aurora kinase B. These studies often involve structure-activity relationship analyses to optimize potency and selectivity. Additionally, Tran's work has explored the use of bifunctional molecules, like O’PROTACs and HDACs/BRD4 inhibitors, to achieve targeted protein degradation and oncolytic effects. Publications also indicate research into the delivery mechanisms of therapeutic oligonucleotides and the CD36-mediated endocytosis of proteolysis-targeting chimeras. Tran has collaborated with researchers at the University of Arkansas for Medical Sciences, including Yuet‐Kin Leung and Brendan Frett, contributing to a body of work in drug discovery and molecular mechanisms of disease.
Metrics
- h-index: 6
- Publications: 12
- Citations: 202
Selected Publications
-
Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor (2025)
-
CD36-mediated endocytosis of proteolysis-targeting chimeras (2025)
-
Mi-2β promotes immune evasion in melanoma by activating EZH2 methylation (2024)
-
An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L (2023)
-
Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas (2023)
-
Delivery of Oligonucleotides: Efficiency with Lipid Conjugation and Clinical Outcome (2022)
-
3-Aminophthalic acid, a new cereblon ligand for targeted protein degradation by O’PROTAC (2022)
-
Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose (2022)
-
Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology (2021)
-
Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors (2021)
Collaboration Network
Top Collaborators
Hongyu Li
The University of Texas Health Science Center at San Antonio (US)
9 shared publications
- Delivery of Oligonucleotides: Efficiency with Lipid Conjugation and Clinical Outcome
- CD36-mediated endocytosis of proteolysis-targeting chimeras
- 3-Aminophthalic acid, a new cereblon ligand for targeted protein degradation by O’PROTAC
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas
Showing 5 of 9 shared publications
Yuet‐Kin Leung
University of Arkansas for Medical Sciences
4 shared publications
In database
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L
- Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors
- Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology
Brendan Frett
University of Arkansas for Medical Sciences
4 shared publications
In database
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
- Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors
- Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology
Wei Yan
University of Arkansas for Medical Sciences (US)
4 shared publications
- CD36-mediated endocytosis of proteolysis-targeting chimeras
- 3-Aminophthalic acid, a new cereblon ligand for targeted protein degradation by O’PROTAC
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Anupreet Kharbanda
University of Arkansas for Medical Sciences
3 shared publications
In database
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors
- Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology
Lingtian Zhang
University of Arkansas for Medical Sciences (US)
3 shared publications
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors
- Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology
Xiuqi Wang
University of Arkansas for Medical Sciences
3 shared publications
In database
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Zhenyu Wang
The University of Texas Health Science Center at San Antonio (US)
3 shared publications
- 3-Aminophthalic acid, a new cereblon ligand for targeted protein degradation by O’PROTAC
- Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Marialuisa Moccia
University of Naples Federico II (IT)
2 shared publications
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Francesca Carlomagno
University of Naples Federico II (IT)
2 shared publications
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Jingwei Shao
University of Arkansas for Medical Sciences
2 shared publications
In database
- CD36-mediated endocytosis of proteolysis-targeting chimeras
- 3-Aminophthalic acid, a new cereblon ligand for targeted protein degradation by O’PROTAC
Tsigereda Weldemichael
University of Arkansas for Medical Sciences
2 shared publications
In database
- Delivery of Oligonucleotides: Efficiency with Lipid Conjugation and Clinical Outcome
- An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L
Jungang Chen
Winthrop Rockefeller Foundation (US)
2 shared publications
- CD36-mediated endocytosis of proteolysis-targeting chimeras
- Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas
Zhiqiang Qin
Winthrop Rockefeller Foundation (US)
2 shared publications
- CD36-mediated endocytosis of proteolysis-targeting chimeras
- Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas
Gunaganti Naresh
University of Arkansas for Medical Sciences
2 shared publications
In database
- An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Similar Researchers
Based on overlapping research topics
Anupreet Kharbanda
University of Arkansas for Medical Sciences
Computational Drug Discovery Methods
Cancer Treatment and Pharmacology
Drug Discovery
Baku Acharya
University of Arkansas for Medical Sciences
Computational Drug Discovery Methods
Cancer Treatment and Pharmacology
Protein Degradation and Inhibitors
Fengping Lv
University of Arkansas for Medical Sciences
Computational Drug Discovery Methods
Cancer Treatment and Pharmacology
Protein Degradation and Inhibitors
Baha’a Jabali
University of Arkansas for Medical Sciences
Computational Drug Discovery Methods
Cancer Treatment and Pharmacology
Drug Discovery
Jaideep B. Bharate
University of Arkansas for Medical Sciences
Computational Drug Discovery Methods
Cancer Treatment and Pharmacology
Drug Discovery
Jingwei Shao
University of Arkansas for Medical Sciences
Computational Drug Discovery Methods
Protein Degradation and Inhibitors
Cancer-related molecular mechanisms research